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Identification of cancer stem cells is crucial for advancing cancer biology and therapy. Several markers including CD24, CD44,
CD117, CD133, the G subfamily of ATP-binding cassette transporters (ABCG), epithelial specific antigen (ESA) and aldehyde
dehydrogenase (ALDH) are used to identify and investigate human epithelial cancer stem cells in the literature. We have now
systemically analyzed and compared the expression of these markers in fresh ovarian epithelial carcinomas. Although the
expression levels of these markers were unexpectedly variable and partially overlapping in fresh ovarian cancer cells from
different donors, we reliably detected important levels of CD133 and ALDH in the majority of fresh ovarian cancer.
Furthermore, most of these stem cell markers including CD133 and ALDH were gradually lost following in vitro passage of
primary tumor cells. However, the expression of ALDH and CD133, but not CD24, CD44 and CD117, could be partially rescued
by the in vitro serum-free and sphere cultures and by the in vivo passage in the immune-deficient xenografts. ALDH1 and
CD1331 cells formed three-dimensional spheres more efficiently than their negative counterparts. These sphere-forming cells
expressed high levels of stem cell core gene transcripts and could be expanded and form additional spheres in long-term
culture. ALDH1, CD1331 and ALDH1CD1331 cells from fresh tumors developed larger tumors more rapidly than their negative
counterparts. This property was preserved in the xenografted tumors. Altogether, the data suggest that ALDH1 and CD1331
cells are enriched with ovarian cancer-initiating (stem) cells and that ALDH and CD133 may be widely used as reliable markers
to investigate ovarian cancer stem cell biology.
Ovarian carcinoma is a deadly disease characterized by late
diagnosis, early metastasis and resistance to therapy.
Although the majority of patients initially respond to plati-
num-based chemotherapy, most will subsequently succumb
to chemoresistant, recurrent disease. Long-term treatment
success is limited by the development of chemoresistant dis-
ease. This may be partially due to the immunosuppressive
networks formed in the human ovarian cancer microenviron-
ment. In the last several years, our research team has focused
on the human ovarian carcinoma microenvironment and has
demonstrated that immune cells in human ovarian carcinoma
have been reprogrammed by active tumor-mediated processes
to defeat tumor immunity and in turn temper the clinical ef-
ﬁcacy of chemotherapy.1–4
It is also possible that existing therapies primarily target
the bulk of the ovarian carcinoma cell population rather than
the cancer-initiating cells (or stem cells or stem-like cells).5–11
Although multiple markers including CD44, CD117,12
CD13313,14 and Hoechst positive ‘‘side population’’15 are used
to identify ovarian cancer stem cells, the concept of ovarian
cancer stem cells remains controversial, and the nature of
these ovarian cancer stem cells has not been well deﬁned in
fresh ovarian cancer and primary tumor cells. Aldehyde de-
hydrogenase (ALDH) has been used to investigate multiple
human cancer stem cells.16–22 Recent reports showed that
ALDHþ ovarian cancer cells possess stem cell properties.23,24
However, it is not well understood if ovarian cancer stem
cells universally express ALDH, CD133 and other markers
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and if ALDH expression is phenotypically and functionally
associated to many other reported markers for ovarian cancer
stem cells. In our study, we revisited this issue and examined
fresh ovarian cancer tissues, primary ovarian cancer cells and
xenografted ovarian cancer cells in our laboratory and
focused our studies on identifying and comparing potential
ovarian cancer stem cells and the regulatory effects of in vitro
and in vivo environments on the property of ovarian cancer
stem cells.
Material and Methods
Human subjects
We studied previously untreated patients with epithelial ovar-
ian carcinomas (n ¼ 25). The patients gave written informed
consent. Our study was approved by the University of
Michigan.
Cells and tissues
Cells and tissues were obtained from ascites and tumors as
described.25–27 Fresh tumors were processed into single cell
suspension as described and immediately used for enrich-
ment or ﬂow analysis.25–27 Potential cancer stem cells were
enriched by depleting CD45-PE positive immune cells,
including macrophages, myeloid dendritic cells, plasmacytoid
dendritic cells, B and T cell subsets (PE-selection kit;
StemCell Technologies, Vancouver, Canada) and sorted with
FACSAria (Becton Dickinson, San Jose, CA) as we previously
described.25–27 Dead cells were excluded. Cell purity was
>98% as conﬁrmed by ﬂow cytometry (LSR II, Becton Dick-
inson, San Jose, CA). Primary ovarian cancer cells were
established from fresh ascites or/and tumor tissues. Tumor
cells were initially enriched with double Ficoll separation
with 100% Ficoll-Metrizoate (1.077 g/ml) on the bottom, fol-
lowed by a layer of 75% Ficoll-Metrizoate on the top (1.057
g/ml). Tumor cells were enriched on the top layer. Other
cells were on the middle layer, and the debris containing
erythrocytes and polynuclear cells was on the lower layer.
The enriched tumor cells were further sorted with high-speed
sorter (FACSAria, Becton Dickinson, San Jose, CA). The cells
were either cultured under conventional condition [10% fetal
calf serum (FCS), RPMI medium, all from GIBCO, Invitro-
gen, Carlsbad, CA] as a monolayer or serum-free (X-vivo20;
Lonza, Basel, Switzerland) and sphere culture conditions
(nonadherent, X-vivo20; Lonza, Basel, Switzerland).
Flow cytometry analysis
Cells were stained with speciﬁc antibodies against human
CD3, CD4, CD8, CD11b, CD11c, CD14, CD19, CD24, CD44,
CD117, CD133, Annexin V (BD Biosciences, San Diego, CA)
and ESA (StemCell Technologies, Vancouver, Canada). Sam-
ples were acquired on a LSR II, and data were analyzed with
DIVA software (BD, Biosciences, San Diego, CA). The
ALDEFLUOR (ALDH) kit (StemCell Technologies, Vancou-
ver, Canada) was used to identify and sort ALDHþ cells with
high ALDH enzymatic activity by FACSAria as described.16,17
Brieﬂy, single cells were suspended in ALDH assay buffer
containing ALDH substrate-BAAA (BODIPY-aminoacetalde-
hyde) and incubated at 37C for 40 min. In each experiment,
the speciﬁc ALDH inhibitor diethylaminobenzaldehyde was
used as negative control at 50 mmol/l. Other cells including
CD133þ and ABCG2þ were sorted based on the surface anti-
gen expression.
Immunoﬂuorescence analysis
Immunoﬂuorescence analysis was performed as described.27,28
Tissues were stained with monoclonal mouse anti-human-
CD133 (1/100 dilution; Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany) followed by Alexa Fluor 568-conjugated
goat anti-mouse IgG (2 lg/ml; Molecular Probes, Invitrogen,
Carlsbad, CA) and with Fluorescein isothiocyanate (FITC)-
conjugated mouse anti-human ESA (1/100 dilution; StemCell
Technologies, Vancouver, Canada). Positive cells were quanti-
ﬁed by ImagePro Plus software (Media Cybernetics, Inc., Silver
Spring, MD) and expressed as the mean of the percent positive
cells 6 standard deviation in 10 high-powered ﬁelds using
confocal microscopy.
Sphere formation
The sphere assay was performed as described.16,17 Brieﬂy, tu-
mor cells or electronically sorted tumor cell subsets were
plated in ultralow attachment plates (Corning, One River-
front Plaza, NY) in serum-free EBM-2 or X-VIVO medium
(Lonza, Basel, Switzerland) supplemented with 5 lg/ml insu-
lin (Sigma-Aldrich, St. Louis, MO) and 20 ng/ml human
recombinant epidermal growth factor (Invitrogen, Carlsbad,
CA), at a density of 1,000–10,000 viable cells/well. Spheres
(>50 lm) were counted for 1–6 weeks.
Quantitative real-time polymerase chain reaction (PCR)
Total RNA was isolated with Qiagen Reagent (Qiagen, Valen-
cia, CA). The RNA was reverse transcribed into cDNA using
oligo-dT primers and SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, CA), according to the manufacturer’s
instructions. The primer sequence combinations spanned
contact sequences of subsequent exons. For ampliﬁcation, the
SyberGreen qPCR mix was used (Invitrogen, Carlsbad, CA).
Each reaction was run in triplicate on the Mastercycler
machine (Eppendorf, Hamburg, Germany) and was normal-
ized to housekeeping gene GAPDH transcripts.
In vivo tumor formation
Ovarian tumor cell subsets (102-5  106) in 100 ll of buf-
fered saline were subcutaneously injected into dorsal tissues
of female NOD/Shi-scid/IL-2Rcnull [nitric oxide dismutate-
severe combined immunodeﬁciency IL-2 receptor c null mice
(NSG)] mice (6–8 weeks old; Jackson Laboratory, Bar Har-
bor, ME), similar to our studies in NOD.SCID mice.28,29 Tu-
mor size was measured twice weekly using calipers ﬁtted
with a Vernier scale. Tumor volume was calculated based on
three perpendicular measurements.28,29
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Figure 1. Cancer stem cell markers in fresh ovarian cancer. Fresh ovarian tumors were separated into single cell suspensions. Cells were
stained for lineage-speciﬁc and cancer stem cell markers and apoptotic cells. (a) Phenotype of fresh ovarian cancer cells. Multicolor ﬂow
cytometry analysis was performed on the cells by gating on viable linCD45CD34 cells. Epithelial ovarian cancer cells were deﬁned as
viable linCD45CD34ESAþ cells. The characteristics of linCD45CD34ESAþ cells in forward scatter (FSC)/side scatter (SSC) are shown.
One of 25 representative patients is shown. (b and c) Cancer stem cell markers in fresh ovarian cancer cells. Results are expressed as the
percentage of speciﬁc population in linCD45CD34ESAþ cells (b and c). Original dot plots showed high (upper panel) and low (lower
panel) expression of given cancer stem cell marker in fresh ovarian cancer cells (c). (d and e) The expression of CD133 and ESA in fresh
ovarian cancer tissues: high levels of CD133 (d) and low levels of CD133 (e).
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Statistical analysis
Differences in cell surface molecule expression were deter-
mined by v2 test, and the differences in other variables were
determined by Mann-Whitney test, with p < 0.05 being con-
sidered signiﬁcant.
Results
Expression of multiple potential cancer stem cell markers
in fresh ovarian tumors
CD24, CD44, CD117, CD133, ABCG2 and ESA are used to
deﬁne cancer stem cells in multiple human epithelial can-
cers30–32 including ovarian cancer.12–14 Recently, ALDH was
also applied for identifying cancer stem cells.7–9,19,20,30–33 We
initially examined the expression of these markers in fresh
ovarian tumor cells. To this end, ovarian tumors were
excised, and single cell suspensions were made. Suspended
tumor cells were stained with lineage markers (anti-CD45,
anti-CD34 and anti-ESA), stem cell markers and 7-AAD. All
analyses were gated on viable cells. Immune cells (CD45þ),
endothelial cells and hematopoietic progenitor cells (CD34þ)
and other nonepithelial cells (ESA) were gated out for stem
cell marker analysis (Fig. 1a). Multicolor ﬂow cytometry
analysis revealed a signiﬁcant linCD45CD34ESAþ cell
population in fresh ovarian cancer tissues (Fig. 1a). This pop-
ulation was also observed in the fresh ascites ﬂuid in patients
with ovarian cancer (not shown). We reasoned that the
potential ovarian cancer stem cells could be included in
linCD45CD34ESAþ cell population.
LinCD45CD34ESAþ cell population was further ana-
lyzed for potential cancer stem cell markers. We observed
that there were 7–100% CD24þ cells, 0.5–85% CD44þ cells,
0–10% CD117þ cells, 0.7–6.2% CD133þ cells, 1.8–14%
ABCG2þ cells and 0.3–7.1% ALDHþ cells in epithelial cells
isolated from fresh ovarian tumors (Figs. 1b and 1c). Immune
ﬂuorescence staining conﬁrmed that CD133þ cells were
Figure 2. Relationships between multiple cancer stem cell markers in fresh ovarian cancer. Fresh ovarian tumors were separated into single
cell suspensions. Cells were stained for stem cell markers (CD133, ALDH, ABCG2 and CD44) and linkage markers (CD45, CD34 and ESA).
Tumor cells were determined as described in Figure 1a. (a–c) The phenotypic characteristics of CD133þ tumor cell populations. Results are
shown as the percentage of CD133þ cells in different tumor populations. Original dot plots showed the relationship between ALDH, ABCG2
and CD133 (b and c). As a control for ALDH activity, the DEAB inhibitor has been used (see Material and Methods section) (b). (d and e)
The phenotypic characteristic of CD44þ tumor cells. Results are shown as the percentage of CD44þ cells in different tumor populations.
Original dot plots showed the relationship between ALDH and ABCG2 (n ¼ 12).
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ESAþ in fresh ovarian cancer tissues (Figs. 1d and 1e). As
the expression levels of cancer stem cell markers were consid-
erably variable from patient to patient, we showed the levels
of cancer stem cell marker expression in individual patients
(Fig. 1b), as well as the high levels of expression [Figs. 1c
(upper panel) and 1d] and low levels of expression [Figs. 1c
(lower panel) and 1e] of each marker from two representative
ovarian cancers. The data indicate that fresh ovarian cancer
cells express variable levels of multiple potential cancer stem
cell markers.
Relationships between multiple cancer stem cell markers
in fresh ovarian tumors
We next examined the relationships between cancer stem cell
markers in fresh ovarian tumors. High levels of CD24 expres-
sion and limited CD117 expression were detected in the ma-
jority of fresh ovarian cancer cells (Fig. 1b). We focused on
the expression of CD133, ALDH, ABCG2 and CD44, but not
CD24 and CD117. On average, CD133 expression signiﬁ-
cantly overlapped with the expression of ALDH and ABCG2.
Only 3% of all epithelial tumor cells were CD133þ, whereas
14% of ALDHþ and 25% of ABCG2þ cells also expressed
CD133 (Figs. 2a and 2b). There were 10-fold more ALDHþ
cells in CD133þ than CD133 cells (Fig. 2b). Similarly, the
fraction of ABCG2þ cells was higher in CD133þ than
CD133 cells (Fig. 2c). We next analyzed CD44þ cells.
Approximately 40–80% ALDHþ, ABCG2þ and CD133þ cells
also expressed CD44 (Figs. 2d and 2e). Thus, the expression
of these markers is highly variable and overlapping from
patient to patient.
In vivo tumorigenesis of ALDH1 and CD1331 cells in fresh
ovarian tumors
ALDH, CD133 and other potential stem cell markers have
not been directly compared to stem cell markers in fresh
ovarian cancer from the same patients. To determine and
compare the in vivo tumorigenesis of cancer stem cells, we
electronically sorted ALDHþ, CD133þ and ABCG2þ cells
from fresh ovarian tumors. Variable numbers of sorted cells
were immediately implanted into NSG mice by subcutaneous
injection, and tumor formation was followed for up to 48
days. The capacity of in vivo tumor formation with the sorted
cells was different from patient to patient (Table 1). In six
individual patients, we found that the rate of tumor forma-
tion was reliably higher in mice received different numbers
of ALDHþ cells (Fig. 3a), CD133þ cells (Fig. 3b) and
ALDHþCD133þ cells (Fig. 3c; Table 1), than that of received
ALDH or CD133 or ALDH-CD133. Furthermore,
although ALDH, CD133 and ALDHCD133 cells could
be tumorigenic (Table 1; Figs. 3a–3c), the tumor volumes
were smaller than their positive counterparts (Figs. 3b and
3c). When we isolated and analyzed tumor cells from the ﬁrst
xenografted tumors, similar percentages of ALDHþ and
CD133þ cells were generated from the NSG mice inoculated
with ALDHþCD133þ, ALDHþCD133 and ALDHCD133þ
cell populations from the same donor (Table 2). When
ALDHþ, CD133þ, ALDHþCD133þ or ALDHCD133 pop-
ulations were further isolated from the newly formed xeno-
grafted tumors and inoculated into NSG mice, similar tumor-
forming capacity was observed (Fig. 3c, not shown). Interest-
ingly, Hematoxylin & Eosin staining revealed that tumors
forming from ALDHþ, CD133þ, ALDHþCD133þ or
ALDHCD133 populations were histologically similar (Sup-
porting Information Fig. 1). ABCG2þ and ABCG2 cells
were tumorigenic but formed comparable tumors (not
shown). The data indicate that ALDHþ and CD133þ cells
are able to generate heterogeneous tumor populations in vivo
and further support that fresh tumor ALDHþ and CD133þ
cells are enriched with cancer stem cells.
ALDH1 and CD1331 cells form spheres
One of the key features of cancer stem cells is their capacity
of self-renewal. To further functionally deﬁne the stem cell
property, we performed the sphere assay with sorted fresh
ovarian cancer cells as described.16,17 To minimize in vitro
manipulation, we initially cultured the bulk cells. We
observed that culturing the bulk of fresh ovarian cancer cells
resulted in sphere formation. However, deletion of ALDHþ
cells or CD133þ cells dramatically reduced the quantity and
size of spheres formed. Simultaneous deletion of ALDHþ and
CD133þ cells resulted in drastic reduction of sphere forma-
tion (Figs. 4a and 4b). As a conﬁrmatory experiment, we
showed that sorted ALDHþ, CD133þ and ALDHþCD133þ
cells were more efﬁcient in sphere formation than their nega-
tive counterparts (Fig. 4c). We next examined if the sphere
cells could be expanded and kept sphere-forming capacity.
The sphere cells were harvested and subjected to further
sphere culture. As expected, the sphere cells were able to
form and expand spheres in culture for more than 2 months
(Fig. 4d). Furthermore, although it was mechanistically
Table 1. The rate of tumor formation from different tumor
populations in NSG mice
Rate of
tumor
formation
Number of inoculated cells
2,000 cells 5,000 cells
10,000
cells
% N % N % N
CD133þ 33 1/3 60 3/5 100 2/2
CD133 20 1/5 20 1/5 50 2/4
ALDHþ 80 4/5 83 5/6 100 2/2
ALDH 20 1/5 33 2/6 75 3/4
CD133þALDHþ 100 2/2 100 2/2 100 2/2
CD133ALDH 0 0/2 0 0/2 50 1/2
Note: CD133þ, ALDHþ, CD133þALDHþ and their negative counterparts
were sorted from fresh human ovarian cancer and injected into NSG
mice as described in Figures 1a and 1b. The rate of tumor formation
(%) was shown in mice that received different numbers of tumor cell
subpopulations. The observation time is up to 48 days.
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unknown, we noticed that the morphological appearance of
the spheres was different from one donor to another (Fig.
4d). We quantiﬁed and compared selected stem cell core
genes in sphere cells and conventional cultured primary pa-
rental tumor cells. Real-time The polymerase chain reaction
(PCR) revealed that the levels of SOX2, OCT3/4 and
NANOG were higher in sphere cells than parental cells (Fig.
4e). ALDHþ and CD133þ cells were enriched in the sphere
cells (Figs. 4b and 4c). Altogether, these data suggest that
ALDHþ and CD133þ cells are capable of self-renewal in vitro
(Fig. 4) and in vivo (Fig. 3) and that tumor-initiating cells or
cancer stem cells are enriched with ALDHþ and/or CD133þ
cells.
Figure 3. In vivo tumorigenicity of ALDHþ, CD133þ and ALDHþCD133þ cells. (a and b) In vivo tumor formation: 2,000 ALDHþ and ALDH
cells (a), 2,000 CD133þ and CD133 cells (b) and 2,000–10,000 ALDHþCD133þ cells and ALDHCD133 cells were electronically sorted
from fresh ovarian tumors and injected into NSG mice (n ¼ 5). Tumor volumes were measured. Cells in (a) and (b) were from one donor.
Cells in (c) were from a different donor. One of three independent experiments is shown.
Table 2. The percentage of different tumor populations from tumor
xenograft in NSG mice
Inoculated
cell type
Xenograft tumor cell type
Patient 1 Patient 2
CD1331 ALDH1 CD1331 ALDH1
ALDHþCD133þ 28% 6% 11% 11%
ALDHþCD133 26% 3% 15% 13%
ALDHCD133þ 25% 3% 14% 9%
Note: CD133þ, ALDHþ and CD133þALDHþ cells were isolated and
sorted from tumors formed in the NSG mice and were injected into new
NSG mice as described in Figs. 1a and 1b. The percentage of CD133þ
and ALDHþ cells was analyzed in the total tumor population from NSG
mice from two patients. The observation time is up to 48 days.
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Cancer stem cell markers in fresh cancer cells, primary
cancer cells and xenograft tumors
Majority of previous investigators have used established or/
and commercialized ovarian cancer cell lines to conduct can-
cer stem cell research. Our research team has established
multiple primary cancer cell lines from patients with ovarian
cancer. We examined and compared cancer stem cell markers
in fresh tumor cells, primary ovarian cancer cell lines and tu-
mor cells cultured in vitro in different conditions and in tu-
mor cells isolated from xenograft tumors. We observed that
fresh OC18 cells contained a signiﬁcant CD133þ population
(Fig. 5a). However, following the conventional culture with
10% FCS, the proportion of cells expressing CD133 gradually
decreased from 4–5% (Fig. 5a, upper panel) of the total pop-
ulation to 0–0.2% (Fig. 5a, lower panel) after 6 weeks in cul-
ture. Similar loss was observed for ALDH expression (not
Figure 4. Sphere formation of ALDHþ, CD133þ and ALDHþCD133þ cells. (a and b) Sphere-forming ovarian cancer cells were enriched in
bulk ALDHþ and CD133þ cells. The sphere-forming assay was performed with bulk ovarian cancer cells, and cells depleted for CD133 and/
or ALDH. Numbers of spheres were expressed as mean 6 SEM (n ¼ 4) derived from three different patients. (c) The sphere-forming ovarian
cancer cells were enriched in sorted primary ALDHþ, CD133þ and ALDHþCD133þ cells. The sphere-forming assay was performed with
sorted ALDHþ, CD133þ, ALDHþCD133þ and total cells. Numbers of spheres were expressed as mean 6 SEM (n ¼ 4) derived from three
different patients. (d) Different morphological appearance of spheres and sphere expansion from different patients. Different sphere
appearances were observed from different patients (type A, upper panel; type B, lower panel). Primary sphere cells formed additional
spheres in the long-term culture. Results were shown from two patients. (e) High levels of stem cell core gene transcripts in sphere cells.
Real-time PCR was conducted with parental cells and sphere-forming cells for stem cell core genes. Results are expressed as the mean
values relative to GAPDH 6 SD. Three experiments were run in triplicates, p < 0.01.
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Figure 5. Cancer stem cell markers in fresh, primary and xenografted ovarian tumor cells. (a) Cancer stem cell markers in fresh and primary
ovarian cancer cell lines. Fresh tumor cells were directly isolated from fresh ovarian cancer ascites or tumor tissues. The cells were cultured for
3–6 weeks in conventional culture medium (10% FCS). The expression of cancer stem cells was determined by ﬂow cytometry. Results were
expressed as the percentage of certain stem cell marker positive cells. One of six experiments is shown. (b) Cancer stem cell markers in
xenograft-derived ovarian cancer cell lines: 5 106 cells from the culture of primary ovarian cancer cell lines were injected into NSGmouse to
form tumor. Xenograft-derived tumor cells were stained for stem cell markers. Results were expressed as the percent of positive cells in total
tumor cells. Human tumor cells in the xenografts were determined by gating on H-2Kb7-AAD cells. (c) Cancer stem cell markers in the cultured
xenograft-derived ovarian cancer cell lines in conventional culture. Human tumor cells in the xenografts were obtained from xenografts as
described (b). The cells were cultured with 10% FCS from 0 to 6 weeks. The cultured xenograft-derived tumor cells were stained for stem cell
markers. Results were expressed as the percent of positive cells in total tumor cells. (d) Cancer stem cell markers in the cultured primary and
xenograft-derived ovarian cancer cell lines in serum-free condition. Primary tumor cells were cultured for 6 weeks in conventional condition
(upper panel) and were subsequently subjected to serum-free culture for 12 hr (upper panel). The cells were stained for stem cell markers.
Results were expressed as the percent of positive cells in total tumor cells. Similar experiments were realized with xenograft-derived tumor cells.
One of ﬁve experiments is shown (b–d).
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shown). The loss of CD133 expression was universally
observed in all primary ovarian cancer cell lines we estab-
lished. Furthermore, after more than 6–8 weeks in conven-
tional culture, the expression of CD24, CD44, CD117 and
ABCG2 was either largely reduced or lost completely as com-
pared to fresh ovarian cancer cells (Fig. 5a).
We next investigated whether the lost stem cell markers
could be recovered in the in vivo xenograft passages or in
vitro serum-free culture. We inoculated the in vitro cultured
primary tumor cells (Fig. 5a) into NSG mice. These cells
formed tumors in vivo. The tumor cells were subsequently
isolated from the NSG mice for multiple stem cell marker
analysis (Figs. 5b–5d). We found that xenograft-derived
tumors expressed appreciable levels of ALDH (Fig. 5b, upper
panel), CD133 and ABCG2 (Fig. 5b, lower panel), but negli-
gible levels of CD44 and CD117 (Fig. 5b, lower panel). When
the xenograft-derived tumor cells were further cultured under
conventional condition with 10% FCS, the expression of
ALDH (Fig. 5c, left panel), CD133 (Fig. 5c, right panel) and
ABCG2 (not shown) was gradually disappeared. When the
primary tumor cells (Fig. 5d, upper panel) and xenograft-
derived tumor cells (Fig. 5d, lower panel) were in vitro cul-
tured in serum-free conditions, the expression of CD133 was
partially and rapidly recovered (Fig. 5d). Similar results were
obtained for ALDH expression. However, serum-free and
sphere culture did not rescue (or induce) the expression of
CD24, CD44, ABCG2 and CD117. Altogether, the data indi-
cate that serum-free conditions and in vivo tumor transplan-
tation are able to rescue (or induce) the expression of CD133
and ALDH, but not CD44 and CD117.
Discussion
In this study, we have examined and compared the expres-
sion of multiple cancer stem cell markers in fresh ovarian
cancer and established primary ovarian cancer cell lines and
investigated the stem cell properties of potential ovarian can-
cer stem cells in vitro and in vivo.
We have shown that although the levels of ALDH and
CD133 expression are variable, expression is detectable in the
majority of fresh ovarian tumors. Consistent with the cancer
stem cell concept, ALDHþ and CD133þ cells are able to efﬁ-
ciently form spheres and heterogeneous tumors in vivo with
limited numbers of cells. ALDH is thought to be a marker
for deﬁning stem cells in multiple human epithelial cancers
including breast cancer,16,21 colon cancer,19,20 hepatocellular
carcinoma,18 head and neck squamous cell carcinoma22 and
ovarian cancer.23,24 On the basis of these reports and current
criteria including in vivo tumor formation with limited cells
and sphere formation, we suggest that ALDHþ and CD133þ
cells may be enriched with cancer stem cells in the majority
of human ovarian cancer.
Although ALDH and CD133 can be used to identify ovar-
ian cancer stem cells in fresh ovarian tumors, the expression
of CD133, ALDH and other markers is gradually reduced
following prolonged in vitro cell passages. In support of our
observation, it has been demonstrated that tumor cells grown
under standard serum-containing cell culture conditions
result in the loss of tumor stem cells.34 The loss of stem cell
markers in vitro culture system suggests that the stem cell
phenotype or/and properties may possibly need to be sup-
ported in vivo in the tumor microenvironment and that the
in vitro conventional culture conditions may not be appropri-
ate for maintaining the cancer stem cell phenotype. In sup-
port of this possibility, the expression of cancer stem cell
markers CD133 and ALDH is partially recovered in the in
vivo formed xenograft tumors and in the in vitro serum-free
culture. Our results also indicate that the loss of stem cell
markers may be reversible. However, it is unknown whether
the recovered CD133þ and ALDHþ cells are from original
CD133dim and ALDHdim cells (which may not be detectable
by current ﬂow cytometry technique) or from CD133 and
ALDH cells. It has been suggested that the capacities for
self-renewal and tumor initiation may not be restricted to a
uniform population of stem-like cells, but can be shared by a
lineage of self-renewing cell types.35 Further genetic and
functional studies are needed to analyze if CD133 and ALDH
are functionally and genetically relevant for controlling can-
cer stem cell properties and if fresh and induced (or rescued)
CD133 and ALDH expressing cells are genetically and func-
tionally distinct.36 Interestingly, once the cells are exposed to
conventional culture conditions, the expression of CD133
and ALDH rescued (or induced) by the serum-free culture
conditions or the in vivo tumor passages gets lost again.
Nonetheless, given that the expression of CD133 and ALDH
appears within 12 hr in the in vitro serum-free culture and
that the appearance of their expression is dependent on the
environmental conditions, we speculate that genetic muta-
tions may not be the major cause of driving CD133 and
ALDH induction in our experimental conditions. This does
not contradict with the notion that the combination of multi-
ple genetic changes or/instability is of fundamental impor-
tance in tumorigenesis. Furthermore, fresh and induced
CD133- and ALDH-expressing cells express high levels of
stem cell core genes and efﬁciently form spheres and in vivo
tumors. Altogether, the data support the conclusion that
CD133- and ALDH-expressing cells are enriched with cancer
stem cells and that these cells are important tools for study-
ing ovarian cancer stem cell biology.
In addition to ALDH and CD133, other markers may be
used in ovarian cancer stem cell research. ESA is expressed
in fresh epithelial ovarian tumor cells. The expression of
CD24 and CD44 is highly expressed in many fresh ovarian
tumor cells we examined. ABCG2þ and ABCG2 ovarian
cancer cells are equally tumorigenic. It has been reported that
CD44þ and CD117þ can be used to identify ovarian cancer
stem cells.12,37 Our data show that the expression of CD117
is not detectable in more than 50% of fresh ovarian tumors
and in 100% primary ovarian cancer cells established in 10%
FCS conventional culture. Furthermore, the loss of CD44 and
CD117 expression cannot be rescued by in vivo xenograft
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tumor passage and in vitro sphere culture. Based on these
results, our data suggest that CD133 and ALDH can more
accurately identify ovarian cancer stem cells and can be
broadly used for ovarian cancer stem cell research in the ma-
jority of ovarian cancer. However, given the high heterogene-
ity of ovarian cancer types, it is important to note that
CD44, CD117 and other markers could be used to investigate
cancer stem cells in certain ovarian cancer types. Addition-
ally, we have shown that CD133 and ALDH cells could be
tumorigenic in vivo. It also indicates that CD133 and ALDH
are not exclusive markers for ovarian cancer stem cells.
The majority of published reports on human ovarian can-
cer stem cells used commercially available established ovarian
cancer cell lines (or the unsorted tumors) or ‘‘the cells’’ iso-
lated from the in vitro formed spheres or the mouse xeno-
grafts.12–15,37 Macrophages, ﬁbroblasts and many other cells
express some stem cell markers including CD44 and CD24. As
these cells are substantial populations in the tumor mass and
may promote tumorigenesis, it is important to absolutely avoid
their contamination in the ovarian cancer stem cell compart-
ments. To this end, on the basis of our multicolor ﬂow cytom-
etry analysis, we have excluded all the possible nonepithelial
cell fractions, including the immune cells (e.g., macrophages, T
cells, and B cells), ﬁbroblasts, vascular endothelial cells and
CD34þ progenitors and hematopoietic cells in our studies. We
systemically compared multiple stem cell markers and directly
sorted these cells from fresh human ovarian tumors and inves-
tigated their stemness properties, including self-renewal and in
vivo tumorigenesis. Given that long-term culture may alter
cancer stem cell properties, we have minimized the potential
impact of long-term in vitro culture and the experimental
manipulation on the properties of ovarian cancer stem cells.
One of the key issues in cancer stem cell studies is the regula-
tion of cancer stem cell self-renewal and expansion. These
properties are not autonomous to stem cells, and recent evi-
dence points to a level of external control from the microen-
vironment that deﬁnes the stem cell niche.38,39 This may
explain why tumor stem cell markers are lost in the in vitro
culture and are partially rescued in the in vivo model. Recent
studies demonstrate that IL-640,41 and IL-842 promote cancer
stem cell-mediated tumorigenesis in vivo. We suggest that can-
cer stem cells may renew and expand in the tumor environ-
ment in vivo. The next step is to further deﬁne the tumor envi-
ronmental factors and molecular signaling pathway crucial for
regulating ovarian cancer stem cell properties.
We conclude that ALDH and CD133 are useful and reli-
able markers for investigating human ovarian cancer stem
cells in the majority of patients with ovarian cancer. Our
data indicate that the expression levels of multiple stem cell
markers gradually diminish following prolonged culture in
vitro. Therefore, fresh tumor cells are needed to investigate
cancer stem cell biology.
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